CSIMarket
 
Waters Corp  (WAT)
Other Ticker:  
 
 
Price: $302.7200 $-6.26 -2.026%
Day's High: $309.05 Week Perf: -0.07 %
Day's Low: $ 301.15 30 Day Perf: 2.83 %
Volume (M): 387 52 Wk High: $ 367.21
Volume (M$): $ 117,108 52 Wk Avg: $300.97
Open: $309.05 52 Wk Low: $231.90



 Market Capitalization (Millions $) 22,808
 Shares Outstanding (Millions) 75
 Employees 7,800
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 594
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 96

Waters Corp
Waters Corp is an American scientific instrument and software company that specializes in the design, manufacture, and distribution of analytical instruments used in liquid chromatography, mass spectrometry, and thermal analysis.

The company was founded in 1958 by James L. Waters and is headquartered in Milford, Massachusetts. Over the years, Waters Corp has become a leading provider of advanced analytical solutions for various industries, including pharmaceuticals, life sciences, food and beverages, environmental testing, and more.

Waters Corp offers a wide range of innovative products and services, including LC and LC-MS systems, chromatography columns, sample preparation products, data management software, and technical support. These instruments and services help researchers and scientists analyze and interpret complex data to improve product quality, efficiency, and safety.

The company has a strong focus on research and development, constantly striving to develop cutting-edge technologies that push the boundaries of analytical science. They have also established collaborations with academic institutions and industrial partners to further advance scientific knowledge and contribute to industry advancements.

With a global presence, Waters Corp serves customers in more than 100 countries through a network of direct sales offices, distributors, and service centers. Their dedication to customer satisfaction, product quality, and technical support has earned them a strong reputation in the scientific community.


   


Customers Net Income grew by WAT's Customers Net Profit Margin grew to

1883.91 %

3.67 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
B   -1.48%    
DHR   -1.09%    
HON   -0.51%    
JNJ        3.65% 
MYL        3.65% 
TMO   -1.9%    
• View Complete Report
   



Kewaunee Scientific Corporation

Kewaunee Scientific Corporation Surges with Impressive Earnings Boosted by $9.83 Million Tax Refund

Investors are buzzing with excitement as Kewaunee Scientific Corporation (NASDAQ: KEQU) recently reported impressive financial results for the fourth quarter of the 2024 earnings season. The company showed a remarkable 8.621% increase in revenue, reaching $58.64 million compared to $53.99 million in the previous year. Additionally, Kewaunee posted a staggering bottom-line elevation of 1053.69%, with earnings per share soaring to $3.64 from $0.32 in the prior year reporting period.
This unexpected surge in revenue comes as a surprise to many, especially amidst a challenging time for the Laboratory Analytical Instruments sector, which saw a 3.95% reduction in top-line. Kewaunee's net income also saw a significant increase of 921.85% to $11.179 million, up from $1.094 million in the same quarter last year.

Thermogenesis Holdings Inc

Thermogenesis Holdings Inc Surprises Investors with Impressive Financial Results



Thermogenesis Holdings Inc, a leading player in the industry, recently released its financial results for the most recent fiscal period. The company has managed to reduce its losses on lower revenue, which raises questions about the company's future prospects. This article will analyze the financial performance and explore the potential implications for Thermogenesis Holdings Inc moving forward.
Decreasing Losses and Revenue:
In the most recent fiscal period, Thermogenesis Holdings Inc showcased a significant improvement by reducing its losses. The company reported a loss per share of $-0.46, compared to $-4.07 per share in the corresponding period a year before. This reduction in losses demonstrates the company's efforts to optimize its operations and streamline costs.

Lifeloc Technologies Inc

Challenges and Losses Mount for Lifeloc Technologies Inc during Q1 2024 Financial Period

As a financial analyst, the recent financial results of Lifeloc Technologies Inc for the January to March 31 2024 financial period have been quite concerning. Depleting orders have directly led to diminishing returns, with a decrease in revenue of -0.513% to $2.15 million. The shortfall per share has also increased significantly, from $-0.02 per share in the previous year to $-0.12 per share in the current financial period. This marks a sharp decline in performance from the prior financial reporting period, where income per share was at $0.04 and revenue was at $2.19 million.
The net shortfall for the January to March 31 2024 financial period is at $-0.284 million, a substantial increase from the $-0.054 million reported a year ago. These financial results highlight the challenges that Lifeloc Technologies Inc is currently facing in maintaining profitability and growth.

Scientific Industries Inc

2 Turning Financial Losses into Promising Future Opportunities at Scientific Industries Inc

Scientific Industries Inc (SCND) recently released its financial results for the period ending March 31, 2024. Despite facing challenges in terms of revenue decline, the company managed to reduce its losses, showing some promising signs for the future. This article will provide an overview of SCND's financial performance and analyze the context of the company's market and stock performance.
In the first quarter of 2024, SCND was able to cut its losses on fading revenue. The deficit per share stood at $-0.20, a significant improvement compared to $-0.34 in the same quarter the previous year. However, it is important to note that the revenue decreased by 11.474%, from $2.81 million to $2.48 million, in the same period. This indicates a decline in the company's overall sales performance.

Accelerate Diagnostics Inc

Accelerate Diagnostics Inc sees revenue decrease of -3.165% in Q1 2024



Accelerate Diagnostics Inc. recently released its financial results for the interval closing on March 31, 2024. The report highlights a noticeable decline in revenue, causing a deficit in the company's financial performance. This article aims to outline the key facts and interpret the implications of these results.
1. Decreased Revenue:
In the latest reporting period, Accelerate Diagnostics Inc. experienced a decline in revenue by -3.165%, amounting to $2.72 million. This decrease in revenue demonstrates a challenging business environment. In contrast to the previous year, a drop from $3.03 million, revenue deteriorated by -10.043%.






 

Waters's Segments
 
Products
 Segment     of total Revenue
Service
 Segment     of total Revenue
LC & MS instruments
 Segment     of total Revenue
Chemistry
 Segment     of total Revenue
TA instruments
 Segment     of total Revenue
LC & MS service
 Segment     of total Revenue
TA service
 Segment     of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Waters does not provide revenue guidance.

Earnings Outlook
Waters Corp does not provide earnings estimates.

 
Geographic Revenue Dispersion
United States
Europe
Japan
Asia
Other International




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com